|
Market Closed -
NYSE
21:00:00 24/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 2.410 USD | +1.26% |
|
+5.24% | +33.89% |
| 08-12 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 11 | +356.43% | 2 | |||||
| 1,315.04 | +5.46% | 29 | ||||||
| 272.5 | -0.2% | 22 | ||||||
| 276.59 | +4.56% | 29 | ||||||
| 370.31 | -0.03% | 18 | ||||||
| 154.32 | -2.39% | 21 | ||||||
| 212.3 | +28.5% | 22 | ||||||
| 388.48 | -12.47% | 29 | ||||||
| 309.73 | +3.5% | 23 | ||||||
| 157.41 | +7.27% | 27 | ||||||
| 28.61 | +2.27% | 26 | ||||||
| 563.12 | +2.84% | 25 | ||||||
| 66.21 | -1.59% | 24 | ||||||
| 94.28 | +20.44% | 23 | ||||||
| 21.69 | +14.72% | 20 | ||||||
| 9,350 | +33.82% | 15 | ||||||
| 6,450.19 | +11.27% | 16 | ||||||
| 56.83 | +17.23% | 18 | ||||||
| 72.91 | +55.93% | 17 | ||||||
| 4.214 | +13.96% | 17 | ||||||
| Average | 1,008.79 | +28.08% | 21 | ||||||
| Weighted average by Cap. | 711.52 | +5.37% | 24 |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
